
10 Risks to Assess When Choosing a Work Visa for International Staff
Hiring international staff can open the door to a broader talent pool, global innovation, and a competitive edge. But with opportunity comes complexity, especially when selecting the right U.S. work visa. This article explores the key risk factors HR professionals, hiring managers and founders must consider when choosing a work visa for international hires.
The first step in visa selection is determining whether the candidate qualifies for the chosen visa type. Misalignment here can lead to denials, audits, or worse.
Common Risks: Misunderstanding degree requirements for H-1B visas
Assuming 'extraordinary ability' under O-1 without strong documentation
Using L-1 without sufficient intra-company history
Mitigation Tip: Use corporate immigration platforms like Boundless, which help automate eligibility screening and prepare documentation for common work visas, including H-1B, L, and O visas.
U.S. immigration timelines are notoriously unpredictable. Premium processing may shorten some timelines, but bottlenecks in consulates or USCIS offices can delay onboarding by weeks or months.
Common Risks: H-1B cap lottery delays or rejections
EB green cards are subject to country-specific backlogs (India and China, especially)
Security checks and document requests prolong approval
Mitigation Tip: Plan visa timelines 6–12 months in advance. Monitor Visa Bulletin updates to USCIS processing stages in order to identify delays early.
Once a visa is approved, the employer must maintain compliance with Department of Labor and USCIS rules. Failure to do so can lead to fines or disqualification from future visa sponsorship.
Common Risks: Incorrect wage level filings for H-1B
Incomplete Public Access Files (PAFs)
Misclassification of visa status (e.g., interns misrepresented as employees)
Mitigation Tip: Work with HR platforms and legal partners that maintain digital audit trails. Use structured workflows for onboarding, compensation documentation, and visa updates.
Visa processing can be expensive. Fees vary based on visa type, premium processing, legal counsel, and ongoing compliance.
Average Costs (approximate): H-1B: $5,000–$10,000
L-1: $4,000–$8,000
O-1: $6,000–$12,000
EB Green Cards: $10,000–$20,000 over multiple years
Mitigation Tip: Use transparent, flat-fee platforms for predictable budgeting when hiring international talent. More complex immigration cases might require an immigration attorney or in-house counsel.
Visa constraints can affect job satisfaction, mobility, and retention. Employees waiting years for a green card or dependent on employer sponsorship may feel stuck, or leave when options arise.
Common Risks: Long wait times for EB-2/EB-3 green cards
Spouses unable to work (dependent visa restrictions)
Employees lured by companies offering better immigration pathways
Mitigation Tip: Provide long-term sponsorship roadmaps and support (EB categories), invest in employee experience, and communicate clearly about options and timelines.
Not every visa aligns with your company's size, structure, or global goals. A mismatch can introduce friction.
Examples: L-1 requires a qualifying relationship between foreign and U.S. entities
O-1 demands extensive documentation of individual acclaim
H-1B relies on a lottery (March–April), limiting spontaneity
Mitigation Tip: Consider hybrid solutions: hire offshore temporarily, use remote-first models, or explore cap-exempt H-1Bs (e.g., through nonprofit partnerships or research institutions).
U.S. immigration policy shifts with each administration, and even legal visa holders can be affected by sudden regulatory changes.
Recent Trends: Travel bans, visa suspensions, or executive orders under the Trump administration
Increased scrutiny of STEM-related H-1Bs
Green card backlog reform debates in congress
Mitigation Tip: Monitor immigration policy closely and build redundancy into your talent strategy (e.g., remote teams in Canada or EU). Platforms like Boundless Immigration also offer compliance updates and government alerts.
Top talent often travels with spouses or children. A restrictive dependent policy may deter candidates.
Considerations: H-4 spouses may not be eligible to work without an EAD (Employment Authorization Document)
School access and local licensing for dependents
Permanent residency path for family members
Mitigation Tip: Include family support in relocation packages and immigration planning.
Errors or embellishments in visa applications can lead to denials or blacklisting, even if unintentional.
Examples: Inaccurate job descriptions or inflated credentials
Fake degrees or work experience (especially from third-party firms)
Misuse of Optional Practical Training (OPT) or Curricular Practical Training (CPT)
Mitigation Tip: Conduct thorough reference and credential checks. Centralize application materials and vet with legal oversight.
Can your chosen visa process scale as your company grows?
Questions to ask: Is your legal partner or platform equipped to handle dozens of visas at once?
Will your HR systems track visa milestones at scale?
Can your business model handle recurring sponsorship costs?
Mitigation Tip: Invest in tools for end-to-end visa lifecycle management. Choose partners who can scale with your hiring roadmap.
TIME BUSINESS NEWS

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Politico
37 minutes ago
- Politico
Senate Republicans make steep cuts to wind and solar in updated megabill text
Senate Republicans released updated megabill text late Friday that would make sharp cuts to the Inflation Reduction Act's solar and wind tax credits after a late-stage push by President Donald Trump to crack down further on the incentives. The text would require solar and wind generation projects seeking to qualify for the law's clean electricity production and investment tax credits to be placed in service by the end of 2027 — significantly more restrictive than an earlier proposal by the Senate Finance Committee that tied eligibility to when a project begins construction. The changes came after Trump urged Senate Majority Leader John Thune to crack down on the wind and solar credits and align the measure more closely with reconciliation text, H.R.1, that passed the House, as POLITICO reported earlier on Friday. The changes are likely to put some moderate GOP senators, who have backed a slower schedule for sunsetting those incentives, in a tough position. They'll be forced to choose between rejecting Trump's agenda or allowing the gutting of tax credits that could lead to canceled projects and job losses in their states — something renewable energy advocates are also warning about. The revised text would retain the investment and production tax credits for baseload sources, such as nuclear, geothermal, hydropower or energy storage, as proposed in the Finance Committee's earlier proposal. But it would make other significant changes, including extending a tax credit for clean hydrogen production until 2028. The panel's earlier proposal would have eliminated the credit after this year. And despite vocal lobbying by the solar industry, the proposal would maintain abrupt cuts to tax incentives supporting residential solar power. The committee's earlier proposal would have eliminated that credit six months after the enactment of the bill; now the updated draft proposes repealing it at the end of this year. It would also deny wind and solar leasing arrangements to residential customers from accessing the climate law's clean electricity investment and production tax credits. And it would move up the timeline for certain rules barring foreign entities of concern from accessing those credits. The bill would move up the termination date for electric vehicle tax credits to Sept. 30, compared to six months after enactment in the earlier Finance text. The credit for EV chargers would extend through June 2026. The new text also provides a bonus incentive for advanced nuclear facilities built in communities with high levels of employment in the nuclear industry. And the bill makes metallurgical coal eligible for the advanced manufacturing production tax credit through 2029.
Yahoo
3 hours ago
- Yahoo
H&M sees second quarter 2025 sales, operating profit dip
Swedish multinational clothing retail company H&M recorded fall in its operating profit to Skr5.9bn ($624.3m) for the second quarter ended on 31 May. The operating margin falling to 10.4% from 11.9%. This decline is primarily due to a reduced gross margin and unfavourable currency exchange impacts. After-tax profits stood at Skr3.96bn compared to Skr5.06bn previously, resulting in earnings of Skr2.48 per share, a decrease from Skr3.15 per share. Gross profit for the second quarter of 2025 was Skr31.43bn, resulting in a gross margin of 55.4% compared to 56.3% the previous year. The margin suffered mainly due to a more expensive US dollar, high freight costs, and the company's investments in enhancing the customer offering. Despite these challenges, the external factors are expected to turn favourable in the second half of the year. H&M experienced a 1% increase in sales in local currencies, despite operating with 4% fewer stores than the previous year. When excluding store closures, sales saw a 3% rise. However, when converted to Swedish krona (Skr), net sales decreased to Skr56.71bn from Skr59.61bn, influenced by a strong Skr which had a six percentage point negative currency translation effect. H&M CEO Daniel Ervér said: 'Our plan, with its focus on the product offering, the shopping experience and brand, is again confirmed by the progress we see. The positive development in important areas such as online, H&M womens-wear and H&M Move, as well as continued focus on good cost control, will contribute to a profitable sales development.' Selling and administrative expenses were Skr25.49bn, a slight increase in local currencies by 2%. In the first half of the year, net sales were up 1% in local currencies, with Skr112.05bn in net sales. Gross profit was Skr58.59bn, with a gross margin of 52.3%. Operating profit for the half-year was Skr7.12bn, with a margin of 6.4%. June 2025 sales are expected to increase by 3% in local currencies compared to the same month last year, despite a negative calendar effect. Ervér added: 'In uncertain times with cautious consumers we monitor macroeconomic and geopolitical developments closely and continuously adapt both the customer offering and the business to meet our customers' needs in the best way.' H&M is planning to enter the Brazilian market, with both physical and online stores, in the second half of the year. Portfolio brands, particularly COS, have shown growth, and the company remains focused on improving the product offering and shopping experience. Sustainability efforts have been integrated into operations, yielding recognition from an environmental organisation. Ervér added: 'With a clear plan, a strong financial position, good cost control and committed employees, we see good opportunities for long-term, sustainable and profitable growth.' "H&M sees second quarter 2025 sales, operating profit dip" was originally created and published by Retail Insight Network, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Yahoo
6 hours ago
- Yahoo
BioMarin's ROCTAVIAN Shows Sustained Efficacy, Safety Over 5 Years for Severe Hemophilia A
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) is one of the most undervalued US stocks according to analysts. On June 24, BioMarin Pharmaceutical Inc. presented new 5-year data from its Phase 3 GENEr8-1 trial at the 33rd Congress of the International Society on Thrombosis and Haemostasis/ISTH in Washington, D.C., which took place from June 21 to 25. The data reinforced the long-term efficacy and safety of ROCTAVIAN (valoctocogene roxaparvovec-rvox) as a gene therapy for severe hemophilia A. The GENEr8-1 trial is the longest and largest hemophilia gene therapy study to date, and demonstrated sustained Factor VIII (FVIII) expression and durable bleed control 5 years after a single treatment with ROCTAVIAN. A pharmaceutical plant manufacturing a proprietary synthetic oral form of a C-type natriuretic peptide. FVIII activity remained consistent with previously reported results. Importantly, no new safety signals were observed over the 5-year study period. Across all 134 participants who received ROCTAVIAN in the study, there were no cases of FVIII inhibitors or thromboembolic events, and no treatment-related malignancies were observed. BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) is a biotechnology company that develops and commercializes therapies for life-threatening rare diseases and medical conditions internationally. While we acknowledge the potential of BMRN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the . READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey. Sign in to access your portfolio